N-Acetyl Selank Amidate: A Research Overview

Introduction

N-Acetyl Selank Amidate is a terminally modified analog of the synthetic heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a compound developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural extension of tuftsin, a naturally occurring immunomodulatory tetrapeptide [1]. The defining chemical feature of N-Acetyl Selank Amidate is the dual terminal modification: an acetyl group at the N-terminus and an amide group at the C-terminus, a combination documented in the peptide chemistry literature to confer substantially enhanced resistance to exopeptidase-mediated degradation relative to the unmodified parent sequence [2]. This article provides an educational reference overview of the compound's chemical identity, structural rationale, and pharmacological classification based on published primary literature.

Background

Selank's pharmacological lineage originates with tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide first isolated and characterized at Tufts University by Najjar and Nishioka in 1970 and described in Nature as a phagocytosis-stimulating factor derived from the Fc region of immunoglobulin G [3]. The immunomodulatory and CNS-relevant properties of tuftsin created a productive platform for peptide extension chemistry aimed at compounds with improved metabolic stability.

Research groups associated with Nikolay Myasoedov, Lyudmila Andreeva, and colleagues at the Institute of Molecular Genetics in Moscow produced Selank by appending the tripeptide Pro-Gly-Pro to the C-terminus of the tuftsin sequence [4]. That C-terminal extension was reported to markedly prolong the peptide's in vivo residence time relative to native tuftsin, which undergoes rapid enzymatic hydrolysis. N-Acetyl Selank Amidate extends this stabilization strategy further, applying terminal-blocking chemistry to the already-improved Selank scaffold to produce a research compound designed to minimize exopeptidase degradation as a confounding variable in experimental settings.

Chemistry and Structure

The parent compound Selank carries the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and has the molecular formula C₃₃H₅₇N₁₁O₉ with a molecular weight of approximately 751.9 Da, as registered in the NIH PubChem database (CID 11765600).

N-Acetyl Selank Amidate is distinguished from the parent by two terminal modifications:

• N-terminal acetylation: An acetyl group (CH₃CO–) is covalently attached to the alpha-amino group at the threonine N-terminus, eliminating the free primary amine that serves as a preferred substrate for aminopeptidase enzymes.
• C-terminal amidation: The carboxyl group at the proline C-terminus is converted to an amide (–CONH₂), removing the free carboxylate recognized by carboxypeptidase enzymes.

The molecular formula of N-Acetyl Selank (as listed in PubChem CID 133082488) is C₃₅H₅₉N₁₁O₁₀. The full amidated form replaces the C-terminal carboxylate oxygen with an amide nitrogen-hydrogen pair, altering the terminal molecular weight modestly relative to the acetylated-only form.

Research in peptide chemistry has documented that N-terminal acetylation and C-terminal amidation together confer substantially greater resistance to exopeptidase-mediated hydrolysis than either modification alone [2]. This dual terminal protection strategy has been applied across multiple research peptide scaffolds to extend plasma half-life and facilitate investigation of pharmacological mechanisms without the confound of rapid enzymatic breakdown.

Pharmacological Classification

N-Acetyl Selank Amidate is classified within the literature as a synthetic tuftsin analog with reported activity at the GABAergic neurotransmission system and documented interaction with enkephalin-degrading enzymes [5]. The parent compound Selank has been characterized as a positive allosteric modulator of GABA-A receptors in in vitro and rodent model systems and as an inhibitor of enkephalin-degrading serum enzymes [5,6] — two distinct but pharmacologically coherent mechanisms that together define Selank's place in the GABAergic/enkephalinergic neuropeptide class. A structurally related analog in the same research cluster, N-Acetyl Semax Amidate, applies analogous dual terminal modifications to the Semax scaffold and is investigated under a comparable pharmacological rationale.

Because the terminal modifications flank but do not alter the seven-residue pharmacophore, N-Acetyl Selank Amidate is expected to engage the same receptor systems as the parent Selank sequence. Direct comparative pharmacokinetic or receptor-binding studies characterizing the acetylated/amidated variant specifically remain an active area — the modification's primary contribution documented in the broader peptide chemistry literature is stabilization against enzymatic degradation, which is expected to amplify pharmacological signal in experimental preparations.

Published reviews of peptide-based neuropharmacoligcals from Russian institutions have placed Selank and its structural derivatives within a broader class of regulatory neuropeptides studied for GABAergic and enkephalinergic pharmacology, a classification distinct from classical benzodiazepine anxiolytics despite overlapping receptor system interactions [7].

Discovery History

The terminal modifications defining N-Acetyl Selank Amidate follow standard peptide chemistry practices developed across decades of endogenous neuropeptide analog research. The strategy of blocking peptide termini to extend stability against enzymatic degradation was explored in the context of enkephalin analogs and short regulatory peptides beginning in the 1970s and 1980s. Applying this chemistry to the Selank scaffold represents a direct extension of the parent peptide research program originating at the Institute of Molecular Genetics.

Selank itself was characterized in peer-reviewed publications beginning in the early 2000s, with foundational work on its GABAergic and enkephalin-related pharmacology appearing between 2001 and 2018 [4,5,6]. The acetylated/amidated variant emerged from this research environment, with its design rationale rooted in preserving the Selank pharmacophore while minimizing in vivo degradation as a confounding variable in experimental settings. This design-for-stability approach parallels the modification strategies documented across the broader research peptide literature.

For a detailed account of the Selank research program's origins at the Institute of Molecular Genetics, see the companion history article: N-Acetyl Selank Amidate: Discovery and Research History.

For mechanism of action detail, see N-Acetyl Selank Amidate: Mechanism of Action.

Regulatory Status

Selank received regulatory registration in the Russian Federation as a pharmaceutical product (nasal drop formulation) for anxiety disorders and neurasthenia, as documented by the Institute of Molecular Genetics group and reviewed in the peer-reviewed peptide biopharmaceuticals literature [1]. That program placed Selank among a small cohort of neuropeptide-derived compounds to achieve full regulatory registration anywhere, a milestone that reflects the depth of the underlying research investment.

N-Acetyl Selank Amidate, as a distinct chemical entity incorporating the dual terminal modification, has not been the subject of independent regulatory submissions with the United States Food and Drug Administration, the European Medicines Agency, or equivalent authorities as of the date of this article. The compound is available as a research-use-only material; researchers seeking verified research-grade material may refer to the N-Acetyl Selank Amidate product page for batch documentation. No clinical trial registrations for the acetylated/amidated variant have been identified in ClinicalTrials.gov or equivalent registries; the regulatory history of the parent Selank program in Russia represents the closest institutional precedent for this compound class.

References

1. Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716. PMID: 35456550. DOI: 10.3390/pharmaceutics14040716. PMC: PMC9030433.

2. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1-2):40-56. PMID: 19879969. DOI: 10.1016/j.drudis.2009.10.009.

3. Najjar VA, Nishioka K. "Tuftsin": a natural phagocytosis stimulating peptide. Nature. 1970;228(5272):672-3. PMID: 4116440. DOI: 10.1038/228672a0.

4. Myasoedov NF, Andreeva LA, Samonina GE, Kamenskiy AA. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I P Pavlova. 2004;54(1):76-83. PMID: 14969422.

5. Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskiy II, Zuikov PV, Lygalov AV. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2001;64(4):15-7. PMID: 11550013.

6. Filatova EV, Shadrina MI, Slominsky PA, Boldyrev AA, Lyapina LA, Andreeva LA, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;6:317. PMID: 26793110. DOI: 10.3389/fphar.2015.00317. PMC: PMC4757669.

7. Zozulya AA, Neznamov GG, Siuniakov TS, Kost NV, Gar'kavaia ER, Siuniakov SA, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741. DOI: 10.2174/0929866525666180925143003.